Prostacyclin protects renal tubular cells from gentamicin-induced apoptosis via a PPARα-dependent pathway

Kidney International

Volumn 73, Issue 5, 2008, Pages 578-587

  Hsu, Y H ^a   Chen, C H ^a   Hou, C C ^a   Sue, Y M ^a   Cheng, C Y ^a   Cheng, T H ^a   Lin, H ^b   Tsai, W L ^a   Chan, P ^a   Chen, T H ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Docosahexaenoic acid (DHA); Gentamicin; Peroxisome proliferator activated receptor alpha (PPAR ); Prostacyclin (PGI2); Renal tubular cell

Indexed keywords

CASPASE 3; CASPASE 9; CELL NUCLEUS RECEPTOR; CYTOCHROME C; DOCOSAHEXAENOIC ACID; GENTAMICIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; KIDNEY CORTEX; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 39349102362     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002704     Document Type: Article

References (28)

1. Leehey DJ, Braun BI, Tholl DA et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol 1993; 4: 81-90.
2. Schmitz C, Hilpert J, Jacobsen C et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277: 618-622.
3. El Mouedden M, Laurent G, Mingeot-Leclercq MP et al. Gentamicin-induced apoptosis in renal cell lines and embryonic rat fibroblasts. Toxicol Sci 2000; 56: 229-239.
4. Servais H, Jossin Y, Van Bambeke F et al. Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob Agents Chemother 2006; 50: 1213-1221.
5. Martinez-Salgado C, Eleno N, Morales AI et al. Gentamicin treatment induces simultaneous mesangial proliferation and apoptosis in rats. Kidney Int 2004; 65: 2161-2171.
6. Servais H, Van Der Smissen P, Thirion G et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol 2005; 206: 321-333.
7. Jiang X, Wang X. Cytochrome c-mediated apoptosis. Annu Rev Biochem 2004; 73: 87-106.
8. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41: 1447-1452.
9. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75: 3A-10A.
10. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol 1982; 76: 3-31.
11. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002; 143: 3207-3210.
12. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94: 4312-4317.
13. Boxer LA, Allen JM, Schmidt M et al. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980; 95: 672-678.
14. Mene P, Abboud HE, Dunn MJ. Regulation of human mesangial cell growth in culture by thromboxane A2 and prostacyclin. Kidney Int 1990; 38: 232-239.
15. Yano T, Itoh Y, Kubota T et al. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol 2005; 166: 1333-1342.
16. Chen CH, Lin H, Hsu YH et al. The protective effect of prostacyclin on adriamycin-induced apoptosis in rat renal tubular cells. Eur J Pharmacol 2006; 529: 8-15.
17. Nagothu KK, Bhatt R, Kaushal GP et al. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68: 2680-2693.
18. Li S, Basnakian A, Bhatt R et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990-F998.
19. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23: 432-438.
20. Sivarajah A, Chatterjee PK, Hattori Y et al. Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 2002; 8: BR532-BR539.
21. Adrain C, Brumatti G, Martin SJ. Apoptosomes: protease activation platforms to die from. Trends Biochem Sci 2006; 31: 243-247.
22. Lin Q, Ruuska SE, Shaw NS et al. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 1999; 38: 185-190.
23. Lin H, Lin TN, Cheung WM et al. Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002; 105: 1962-1969.
24. Shyue SK, Tsai MJ, Liou JY et al. Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer. Circulation 2001; 103: 2090-2095.
25. Lim H, Gupta RA, Ma WG et al. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999; 13: 1561-1574.
26. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 197-208.
27. Gupta RA, Tan J, Krause WF et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000; 97: 13275-13280.
28. Hatae T, Wada M, Yokoyama C et al. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001; 276: 46260-46267.